Mission Pharmacal Header

Mission Pharmacal Header

X

Find Novel Gastroenterology Drugs in Preclinical Development in JAPAN

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Daiichi Sankyo","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunic Exercises Option to License Daiichi\u2019s IMU-856","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Daiichi Sankyo"},{"company":"Sosei Heptares","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$481.0 million","upfrontCash":"$44.0 million","newsHeadline":"Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"}]

Sosei Heptares

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System

Details:

GSK licenses global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR® technology and structure-based drug design platform. The licensed products includes an advanced lead preclinical drug as well as multiple differentiated back-up compounds.

Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: GSK

Deal Size: $481.0 million Upfront Cash: $44.0 million

Deal Type: Collaboration December 20, 2020

ASK
US

Upload
your Pipeline Activity

Daiichi Sankyo

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Immunic Exercises Option to License Daiichi’s IMU-856

Details:

The option and license agreement gives Immunic the exclusive rights to commercialization of IMU-856 in all countries.

Lead Product(s): IMU-856

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Immunic Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 08, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY